EGFR EGFRVIII

CI-VAR-00000873Explore in graph →CIViC 1516

Curated evidence

Evidence by cancer (7 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–7 of 7 evidence items across 4 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Colon Adenocarcinoma1
EGFR EGFRVIII	Erlotinib	Predictive	C	Supports Resistance	2	submitted	EID11116 Case report describing a 63-year-old patient with colorectal adenocarcinoma with disease progression after treatment with XELOX-bevacizumab and bevacizumab-FOLFIRI. After the detection of EGFR aberrat… (full text at CIViC) PMID 32162810 · Li et al., 2020 · Open in CIViC	civic
Glioblastoma3
EGFR Amplification AND EGFR EGFRVIII	Afatinib	Predictive	C	Supports Sensitivity Response	2	accepted	EID773 Case report of a 58-year old patient with disease progression after radiotherapy and three temozolomide cycles. Afatinib and temozolomide led to disease regression. At last assessment 63 treatment cyc… (full text at CIViC) PMID 26423602 ·

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Lung Non-Small Cell Carcinoma2
EGFR EGFRVIII	(oncogenic)	Oncogenic	D	Supports Oncogenicity	3	submitted	EID12820 Inducible expression of EGFRvIII in Tet op EGFRvIII; CCSP rtTA transgenic mice produced a clear oncogenic phenotype, with sequential development of atypical adenomatous hyperplasia, adenomas, and ulti… (full text at CIViC) PMID 16672372 · Ji et al., 2006 · Open in CIViC	civic
EGFR EGFRVIII	Neratinib	Predictive	D	Supports Sensitivity Response	2	submitted	EID12821 Tumors driven by EGFRvIII show clear differential sensitivity to EGFR-targeted therapies. In vivo, treatment with the irreversible EGFR/HER2 inhibitor HKI 272 (neratinib) produced an average 88% reduc… (full text at CIViC) PMID 16672372 · Ji et al., 2006 · Open in CIViC	civic

Unmapped disease1unmapped disease
EGFR EGFRVIII	(functional)	Functional	D	Supports Gain Of Function	3	submitted	EID12819 Expression of EGFRvIII in Ba/F3 cells induced IL–3–independent growth, activation of downstream signaling, including phosphorylated EGFR, AKT, and ERK, and robust proliferative capacity, demonstrating… (full text at CIViC) PMID 16672372 · Ji et al., 2006 · Open in CIViC	civic